Biocon Biologics secures US market entry date for Bmab 1200, a proposed biosimilar to Stelara®
Biocon Biologics and Janssen have finalized the settlement agreement to dismiss the pending Inter Partes Review (IPR) for US 10961307 before the Patent Trial and Appeal Board (PTAB) of the United States Patent and Trademarks Office